



DEPARTMENT OF HEALTH & HUMAN SERVICES

JUL - 2 1999

Food and Drug Administration
Rockville MD 20857

6545 '99 JUL -6 P1:41

The Honorable Tim Holden
Member, U.S. House of Representatives
Berks County Services Center
633 Court Street, First Floor
Reading, Pennsylvania 19601

Dear Mr. Holden:

Thank you for your letter of June 21, 1999, on behalf of your constituent, Mr. Kenneth C. Neiman of Birdsboro, Pennsylvania, regarding dietary supplements containing ephedrine alkaloids.

Ephedrine alkaloids are amphetamine-like compounds with potentially strong stimulant effects on the cardiovascular (heart and blood vessels) and nervous systems. The ephedrine alkaloids in dietary supplements are naturally occurring stimulants and usually are derived from one of several species of herbs of the genus Ephedra, sometimes called Ma huang or Chinese Ephedra.

On June 4, 1997, the Food and Drug Administration (FDA or the Agency) published a proposed rule in the Federal Register (FR) regarding the formulation and labeling of dietary supplements containing ephedrine alkaloids. In the proposed rule, the Agency is proposing:

- to make a finding, which will have the force and effect of law, that a dietary supplement is adulterated if it contains 8 milligrams (mg) or more of ephedrine alkaloids per serving, or if its labeling suggests or recommends conditions of use that would result in intake of 8 mg or more in a 6-hour period or a total daily intake of 24 mg or more of ephedrine alkaloids;
- to require that the label of dietary supplements that contain ephedrine alkaloids state, "Do not use this product for more than 7 days";
- to prohibit the use of ephedrine alkaloids with ingredients, or with ingredients that contain substances, that have a known stimulant effect (e.g., sources of caffeine or yohimbine), which may interact with ephedrine alkaloids; to prohibit labeling claims that require long-term intake to achieve the purported effect (e.g., weight loss and body building);

95N-0304

E
C 3695 /ANS

- to require a statement in conjunction with claims that encourage short-term excessive intake to enhance the purported effect (e.g., energy) that, "Taking more than the recommended serving may result in heart attack, stroke, seizure or death"; and
- to require specific warning statements to appear on product labels.

The proposal also articulates FDA's policy that products marketed as alternatives to illicit street drugs are drugs, not dietary supplements.

FDA proposed this rule in response to serious illnesses and injuries associated with the use of dietary supplement products which contain ephedrine alkaloids and in response to the Agency's investigations and analyses of these illnesses and injuries. Reported adverse events range from episodes of high blood pressure, irregularities in heart rate, insomnia, nervousness, tremors, and headaches, to seizures, strokes, and death. As of January 1997, FDA had received over 800 reports of adverse events associated with the use of more than 100 different dietary supplement products which contained, or were suspected of containing, ephedrine alkaloids. The adverse events reports showed consistent patterns of illness and injury among otherwise healthy individuals and those with underlying diseases or conditions. FDA continues to receive additional reports of adverse events associated with the use of these products.


The proposed measures were developed based on FDA's review of its adverse event reports, the scientific literature, and public comments reviewed by the Agency, including comments generated by an October 1995 advisory working group public meeting and an August 1996 public meeting of FDA's Food Advisory Committee. These experts suggested a number of steps the Agency might take to reduce injuries associated with the use of dietary supplements containing ephedrine alkaloids. If implemented, the proposed rule will reduce the risk of adverse events for consumers who use these products.

FDA allowed a 75-day comment period on the proposed rule. On September 18, 1997 (62 FR 48968), that comment period was reopened for an additional 75 days until December 2, 1997. FDA invited written comments on the proposal from the public and industry. All comments received will be reviewed and considered by the Agency in developing the final rule.

Page 3 - The Honorable Tim Holden

We trust this information responds to your concerns. If we may be of any further assistance, please contact us again.

Sincerely,


for Melinda K. Plaisier
Interim Associate Commissioner
for Legislative Affairs

cc: Dockets Management Branch
(Docket #95N-0304)

TIM HOLDEN
6TH DISTRICT, PENNSYLVANIA

www.house.gov/holden

1421 LONGWORTH BUILDING
WASHINGTON, DC 20515-3806
(202) 225-5546

BERKS COUNTY SERVICES CENTER
FIRST FLOOR
633 COURT STREET
READING, PA 19601
(610) 371-9931

SUITE 303
101 N. CENTRE STREET
POTTSTOWN, PA 17901
(570) 622-4212



CONGRESS OF THE UNITED STATES
HOUSE OF REPRESENTATIVES

June 21, 1999

COMMITTEE ON AGRICULTURE
LIVESTOCK AND HORTICULTURE
GENERAL FARM COMMODITIES,
CONSERVATION, AND CREDIT

COMMITTEE ON TRANSPORTATION
AND INFRASTRUCTURE
PUBLIC BUILDINGS AND
ECONOMIC DEVELOPMENT
SURFACE TRANSPORTATION

Ms. Diane Thompson
Associate Commissioner for Legislative Affairs
Food and Drug Administration
Parklawn Building
5600 Fishers Lane, Room 15-55
Rockville, MD 20857

RE: Mr. Kenneth C. Neiman
60 Stonetown Road
Birdsboro, PA 19508

Dear Ms. Thompson:

I am contacting you on behalf of the above-captioned constituent regarding his concern with the FDA restriction of the natural herb Ma Huang.

Enclosed is information I received from Mr. Neiman which further details his situation. Please be assured that I would appreciate your assistance in responding to my constituent's concern. Kindly forward your correspondence to me at my Reading district office.

Thank you for your time and attention to this important matter.

Sincerely,

TIM HOLDEN
Member of Congress

TH/baw

Enclosure

No. 99-4270

TO THE MEMBERS OF THE SENATE AND HOUSE OF REPRESENTATIVES:

We need your help. The Food and Drug Administration has proposed a rule (62FED.REG.30678) that would deny our right to purchase natural dietary supplements which contain the natural herb Ma Huang. This rule would unduly restrict the levels of naturally occurring ephedrine alkaloids found in Ma Huang to a level that would render these dietary supplements useless to the consumer. There are currently approximately Five Million adult Americans who regularly consume dietary supplements containing Ma Huang, which has been used safely throughout the world for over 5,000 years.

The FDA has based their proposed rule on anecdotal information. However, the FDA has admitted that anecdotal information "cannot be used to calculate incidences or estimates of risk." Additionally, we strongly believe that the proposed rule violates the 1994 Dietary Supplement Health and Education Act, which Congress passed to regulate outrageous and unnecessary actions by the FDA regarding dietary supplements.

We urge you to contact the FDA and stop this unnecessary and illegal action on their part. We are writing you on behalf of ourselves and the millions of other Americans who safely use these products on a daily basis. We need our voices to be heard and we are asking you, our elected officials, to make our voices heard.

Sincerely,

Kenneth C. Neuman